Compare Hilton Hotels Corporation Common Stock (HLT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Sana Biotechnology Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.56 (market cap $72.76B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 87× Sana Biotechnology Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Sana Biotechnology Inc for 23 Days on average.
| HLT | SANA | |
|---|---|---|
Market Cap | $72.76B | $836.71M |
Volume | 1,148,634 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $5.92 |
52-Week Low | $256.96 | $2.68 |
Typical Hold Time | 138 Days | 23 Days |
Enterprise Value | $85.78B | $749.96M |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.29, up 0.87% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $12.04B in 2025, with a net income margin of 12.69%, though valuation ratios like a P/E of 47.47 appear elevated. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook is positive with analyst consensus at Buy (57% of 49 analysts) and a $348.11 price target, but risks include high debt levels (debt-to-asset ratio of 73.88% in 2025) and reliance on travel demand. Upside hinges on continued revenue growth and margin stability amid economic uncertainties.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
